Actively Recruiting
A Phase III Extension Study Evaluating Long-Term Safety of Two Tozorakimab Dose Regimens in Adults with Chronic Obstructive Pulmonary Disease and History of Exacerbations
Led by AstraZeneca · Updated on 2026-10-16
59
Participants Needed
13
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the long-term safety of two different dose regimens of tozorakimab in adults with chronic obstructive pulmonary disease COPD who have a history of exacerbations. It is a Phase III, open-label, multicenter extension study including participants who have completed earlier related studies. The study is designed to assess how well participants tolerate the medication over an extended period. Participants receive subcutaneous injections of tozorakimab through pre-filled syringes, following one of two dose regimens based on their prior study participation. The study monitors these treatments chronically, lasting up to several years, to observe safety outcomes. This extension study allows continued dosing and long-term evaluation. During the study, participants will be regularly assessed for adverse events over 2 to 3 years. Researchers will monitor safety through ongoing clinical evaluations and collect data on any side effects experienced. Participants must consent and continue contraceptive use as agreed in previous studies. The study ensures close observation to understand the long-term impact of tozorakimab in managing COPD exacerbations.
CONDITIONS
Brief Title
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here